Japan is considering a new approach to its “special” market expansion re-pricing that would exclude drug sales tied to private…
HOME > BUSINESS
BUSINESS
- Merck Serono Japan Hopes to Boost Erbitux Share by Narrowing Down CRC Patients: President
July 17, 2014
- Chugai, Zeltia Sign Commercialization Agreement for Plitidepsin in Europe
July 17, 2014
- AZ Begins Nexium Clinical Study for Pediatric Use in Japan
July 17, 2014
- Ono President Professes High Hopes for Newly Approved Anticancer Drug Opdivo
July 16, 2014
- Antiepileptic Treatment Aptiom Approved in Canada: Sumitomo Dainippon
July 16, 2014
- Astellas Files Irribow for Diarrhea-Predominant Irritable Bowel Syndrome in Females
July 16, 2014
- Ex-Astellas Chair Sounds Alarm over Oncology-Focused Businesses, Says Govt Finances Will Be Insufficient
July 15, 2014
- Kyowa Kirin’s UK Subsidiary Acquires Archimedes
July 15, 2014
- Otsuka Files NDA for Abilify Successor Drug Brexpiprazole in US
July 15, 2014
- “Favorable Transactions” for Nesp in Return for Support in Clinical Trial: Independent Panel
July 14, 2014
- Astellas, IBL to Study Manufacturing Method for Agent Utilizing Human Fibrinogen
July 14, 2014
- Takata Seiyaku Looks to Sales of 30 Billion Plus Yen by 2016
July 11, 2014
- Astellas Gearing Up to Expand Xtandi Indication Globally: Chief Medical Officer
July 11, 2014
- Astellas Selects Anticancer FLT3/AXL Inhibitor for Fast-Track Development
July 11, 2014
- Nippon Chemiphar Receives Approval for Actos Generic in Hong Kong: President
July 11, 2014
- Ono to Provide University of Tokyo with Access to Its Compound Library
July 11, 2014
- Bayer Yakuhin Adopts Unique Certificate Program to Train Cancer Sales Reps
July 10, 2014
- Novartis Lays Out New Global Guidelines for Investigator-Led Trials
July 10, 2014
- LSI Medience Develops Cardiotoxicity Assessment System Using Myocardial iPS Cells in NEDO-Driven Research Project
July 10, 2014
- Apeiron Begins PI Study of Neuroblastoma Immunotherapy Agent in Japan
July 10, 2014
ページ
Japan has presented its latest draft policy direction for its FY2026 drug pricing reform. While the package includes a string…
Let’s be real: even with the best intentions, AI systems can reflect our own unconscious biases. As Daniel Kahneman and Amos Tversky famously demonstrated in their groundbreaking work on Prospect Theory, humans are prone to cognitive biases that influence our…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…